Clinical Guidelines

Practice Management for Photobiomodulation of the Retina

Share

A new treatment method for intermediate dry age-related macular degeneration (AMD), known as photobiomodulation (PBM), has shown promising results in clinical trials and received FDA authorization in November 2024. Unlike traditional treatments, PBM aims to improve visual function rather than merely slowing disease progression. Administered in clinical settings without anesthesia, the treatment faces reimbursement challenges, particularly with Medicare. The role and regulations around various healthcare professionals administering PBM are also outlined, emphasizing the importance of compliance with state laws.

Original Source(s)

Related Content